Arvinas (NasdaqGS:ARVN) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsAndrew Saik - CFOAngela Cacace - CSOJeff Boyle - Head of Investor RelationsJonathan Miller - Managing Director of Biotech and Pharma Equity ResearchManoj Radder - VPNoah Berkowitz - CMORandy Teel - President and CEOSrikripa Devarakonda - VP of Biotechnology Equity ResearchConference Call ParticipantsDaniel Bronder - Research AnalystDerek Archila - Managing Director and Co-Head of Therapeutics Research & Senior Bi ...

Fulcrum Therapeutics (NasdaqGM:FULC) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsAlex C. Sapir - President and CEOCorinne Johnson - VPGregory Renza - Managing DirectorIain Fraser - SVP of Early DevelopmentJames Condulis - VP of Biotechnology Equity ResearchMartin Steinberg - Professor of Medicine, Pediatrics, Pathology, and Laboratory MedicineMatthew Biegler - Managing DirectorConference Call ParticipantsAnupam Rama - Managing Director and Senior Equity AnalystJoseph Schwartz - M ...

Key Takeaways AI disruption fears sparked a broad selloff led by IBM and payment, delivery and software stocks.Energy and tanker shipping ETFs rose on oil strength and higher freight rates.Biotech strength and a bear ETF offered shelter as Wall Street turned volatile.Concerns about the disruptive impact of artificial intelligence resurfaced on Feb. 23, 2026, triggering a selloff in delivery, payments and software stocks. The wave of anxiety pushed International Business Machines (IBM) to its steepest declin ...

Fulcrum Therapeutics (NasdaqGM:FULC) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Speaker10Good morning, and welcome to Fulcrum Therapeutics' conference call to discuss 12-week data from the 20-milligram cohort of the phase 1b PIONEER trial of pociredir and sickle cell disease. Currently, all participants are in a listen-only mode. This call is being webcast live and can be accessed on the Investors section of Fulcrum's website at www.fulcrumtx.com, where a replay will be available. I'll now turn the ...

Protara Therapeutics (NasdaqGM:TARA) Update / briefing February 24, 2026 08:00 AM ET Company ParticipantsCarla Beckham - Lead Medical Director and Head of Clinical DevelopmentJacqueline Zummo - Co-Founder and Chief R&D OfficerJesse Shefferman - Co-founder, Director and CEOJustine O'Malley - SVP of Investor Relations and Corporate AffairsNeal Shore - Medical DirectorSoumit Roy - Managing Director and Head of Healthcare ResearchStacy Ku - Biotechnology Equity ResearchConference Call ParticipantsAndres Maldona ...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2026 in REGENXBIO Lawsuit - RGNX [Accessibility Statement] Skip NavigationNEW YORK, Feb. 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX).Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any r ...

Protara Therapeutics (NasdaqGM:TARA) Update / briefing February 24, 2026 08:00 AM ET Company ParticipantsCarla Beckham - Lead Medical Director and Head of Clinical DevelopmentJacqueline Zummo - Chief R&D OfficerJesse Shefferman - Co-Founder, Director, and CEOJustine O'Malley - SVP of Investor Relations and Corporate AffairsNeal Shore - Medical DirectorSwayam Sheth - Equity Research AssociateConference Call ParticipantsAndres Maldonado - Senior Biotechnology Equity Research AnalystCharles Zhu - Managing Dire ...

Vir Biotechnology lands a license agreement with Japan's Astellas Pharma for its lead drug candidate. ...

Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - March 16, 2026 Deadline to Join - Contact The Gross Law Firm [Accessibility Statement] Skip NavigationNEW YORK, Feb. 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN).Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not requi ...

Galapagos (NasdaqGS:GLPG) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Speaker5Good day. Thank you for standing by. Welcome to the Galapagos Year-End 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one and one on your telephone. You will hear an automated message advising your hand is raised. To withdraw your ...